Zogenix (ZGNX) Misses Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
March 6, 2018 4:01 PM ESTZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDALast patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504Initiated global Phase 3 clinical trial for ZX008 in Lennox-Gastaut syndrome
EMERYVILLE, Calif., March 06, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2017.
... More